Catalysts / GLUE
Upcoming FDA decisions and readouts we track for Monte Rosa Therapeutics, each with the filing that announced it.
FreeBioList tracks 2 upcoming catalysts for Monte Rosa Therapeutics (GLUE, listed on Nasdaq). They cover 2 programmes: MRT-8102 (Elevated cardiovascular disease risk (NEK7 degrader)) and MRT-2359 (Advanced castration-resistant prostate cancer).
First on the list: the Phase 1 readout for MRT-8102 (Elevated cardiovascular disease risk (NEK7 degrader)), guided by the company to H2 2026. By stage, the upcoming rows are 1 Phase 1 readout and 1 Phase 1/2 readout.
Both rows link to SEC filings (8-K or 6-K). Both have been verified by a person reading the filing itself, most recently on 11 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Monte Rosa Therapeutics GLUE · Nasdaq | MRT-8102 | Elevated cardiovascular disease risk (NEK7 degrader) | H2 2026 company guidance |
Phase 1 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Monte Rosa Therapeutics GLUE · Nasdaq | MRT-2359 | Advanced castration-resistant prostate cancer | Late 2026 company guidance |
Phase 1/2 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList